JHOP Articles

Skip to main content

Cholangiocarcinoma

Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements

Cholangiocarcinoma

Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?

Peer Reviewers

Thank You JHOP Peer Reviewers

FDA Updates

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

FDA Updates

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

FDA Updates

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Updates

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

FDA Updates

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

FDA Updates

Rylaze Received FDA Approval of a New Dosing Regimen

FDA Updates

Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

Page 44 of 196
Results 431 - 440 of 1953